Back to results
US 2016/0101185 A1Published application
Treatment of cancer
AssigneeCerulean Pharma Inc.
InventorsEdward G. Garmey, Scott Eliasof
Life of this patent
Estimating the term…
Abstract
Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.
Claims23
A method of treating cancer in a subject, the method comprising:
- administering a CDP-camptothecin conjugate, particle or composition, wherein the CDP-camptothecin conjugate has the following formula:
- wherein
- is beta cyclodextrin, each D-L- is independently
- or —OH, each comonomer comprises polyethylene glycol (PEG) having a molecular weight of about 2000 to about 5000 Da, n is at least 4 and each D is camptothecin, and at least one D-L- is
- and
- wherein the cancer is associated with increased plasminogen activator inhibitor-1 (PAI-1) expression levels, carbonic anhydrase IX (CAIX) expression levels or topoisomerase-1 (Topo-1) expression levels, as compared to a reference standard.
3 more elements
A method of treating a cancer, in a subject, the method comprising:
- selecting a subject who has cancer associated with increased plasminogen activator inhibitor-1 (PAI-1) expression levels, carbonic anhydrase IX (CAIX) expression levels or topoisomerase-1 (Topo-1) expression levels, as compared to a reference standard and has already received at least one administration of a CDP-camptothecin conjugate, particle or composition, wherein the CDP-camptothecin conjugate has the following formula:
- wherein
- is beta cyclodextrin, each D-L- is independently
- or —OH, each comonomer comprises polyethylene glycol (PEG) having a molecular weight of about 2000 to about 5000 Da, n is at least 4 and each D is camptothecin, and at least one D-L- is
- acquiring PAI-1 expression levels, CAIX expression levels, or Topo-1 expression levels in the subject after one or more administrations of the CDP-camptothecin conjugate, particle or composition;
- wherein the PAI-1 expression levels, CAIX expression levels, or Topo-1 expression levels in the subject are decreased as compared to the PAI-1 expression levels, CAIX expression levels, or Topo-1 expression levels in the subject prior to administration of the CDP-camptothecin conjugate, particle or composition;
- and
- providing one or more administrations of a CDP-camptothecin conjugate, particle or composition, to the subject, to thereby treat the cancer.
5 more elements
A method of evaluating the efficacy of a treatment, the method comprising:
- acquiring a biological sample from a subject having cancer associated with increased plasminogen activator inhibitor-1 (PAI-1) expression levels, carbonic anhydrase IX (CAIX) expression levels or topoisomerase-1 (Topo-1) expression levels as compared to a reference standard, and who has already received at least one administration of a CDP-camptothecin conjugate, particle or composition, wherein the CDP-camptothecin conjugate has the following formula:
- wherein
- is beta cyclodextrin, each D-L- is independently
- or —OH, each comonomer comprises polyethylene glycol (PEG) having a molecular weight of about 2000 to about 5000 Da, n is at least 4 and each D is camptothecin, and at least one D-L- is
- and
- evaluating PAI-1 expression levels, CAIX expression levels, or Topo-1 expression levels in the biological sample as compared to the reference standard or as compared to PAI-1 expression levels, CAIX expression levels, or Topo-1 expression levels prior to administration of the CDP-camptothecin conjugate, particle or composition, to thereby evaluate the efficacy of the treatment.
3 more elements
Dependencies are inferred from the claim text.